FI971783A0 - Adenoviruksia, joissa ei ole elinkykyisiä kontaminoivia partikkeleita, niiden valmistus ja käyttöjä - Google Patents

Adenoviruksia, joissa ei ole elinkykyisiä kontaminoivia partikkeleita, niiden valmistus ja käyttöjä

Info

Publication number: FI971783A0
Authority: FI; Finland
Prior art keywords: preparation; contaminating particles; viable contaminating; adenoviruses lacking; lacking viable
Prior art date: 1994-10-28

Application number

FI971783A

Other languages

English (en)

Swedish (sv)

Other versions

FI971783L (fi

FI971783A7 (fi

Inventor

Patrice Yeh

Michel Perricaudet

Cecile Orsini

Original Assignee

Rhone Poulenc Rorer Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-10-28

Filing date

1995-10-25

Publication date

1997-04-25

1995-10-25 Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa

1997-04-25 Publication of FI971783A0 publication Critical patent/FI971783A0/fi

1997-04-25 Publication of FI971783L publication Critical patent/FI971783L/fi

1997-04-25 Publication of FI971783A7 publication Critical patent/FI971783A7/fi

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0023—Heat
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/04—Heat
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/075—Adenoviridae
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Hematology (AREA)
Toxicology (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

FI971783A 1994-10-28 1995-10-25 Adenoviruksia, joissa ei ole elinkykyisiä kontaminoivia partikkeleita, niiden valmistus ja käyttöjä FI971783A7 (fi)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9413355A FR2726285B1 (fr)	1994-10-28	1994-10-28	Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
PCT/FR1995/001415 WO1996013596A1 (fr)	1994-10-28	1995-10-25	Adenovirus depourvus de particules contaminantes viables, preparation et utilisations

Publications (3)

Publication Number	Publication Date
FI971783A0 true FI971783A0 (fi)	1997-04-25
FI971783L FI971783L (fi)	1997-04-25
FI971783A7 FI971783A7 (fi)	1997-04-25

Family

ID=9468601

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI971783A FI971783A7 (fi)	1994-10-28	1995-10-25	Adenoviruksia, joissa ei ole elinkykyisiä kontaminoivia partikkeleita, niiden valmistus ja käyttöjä

Country Status (13)

Country	Link
US (2)	US6312946B1 (fi)
EP (1)	EP0787199A1 (fi)
JP (1)	JPH10507922A (fi)
KR (1)	KR100424803B1 (fi)
CN (1)	CN1110564C (fi)
AU (1)	AU703539B2 (fi)
FI (1)	FI971783A7 (fi)
FR (1)	FR2726285B1 (fi)
IL (1)	IL115779A0 (fi)
MX (1)	MX9702553A (fi)
NO (1)	NO320090B1 (fi)
WO (1)	WO1996013596A1 (fi)
ZA (1)	ZA959086B (fi)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69535178T2 (de)	1994-06-10	2006-12-14	Genvec, Inc.	Adenoviren-vektor systeme und zelllinien
FR2726285B1 (fr) *	1994-10-28	1996-11-29	Centre Nat Rech Scient	Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
EP0787200B1 (en)	1994-10-28	2005-04-20	The Trustees Of The University Of Pennsylvania	Improved adenovirus and methods of use thereof
WO1996018418A1 (en) *	1994-12-12	1996-06-20	Genetic Therapy, Inc.	Improved adenoviral vectors and producer cells
IL116816A (en) *	1995-01-20	2003-05-29	Rhone Poulenc Rorer Sa	Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
FR2730504B1 (fr) *	1995-02-13	1997-03-28	Rhone Poulenc Rorer Sa	Procede de preparation de genomes d'adenovirus recombinants
US5707618A (en) *	1995-03-24	1998-01-13	Genzyme Corporation	Adenovirus vectors for gene therapy
US6281010B1 (en)	1995-06-05	2001-08-28	The Trustees Of The University Of Pennsylvania	Adenovirus gene therapy vehicle and cell line
ES2333425T5 (es)	1995-06-15	2012-08-28	Crucell Holland B.V.	Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
US6783980B2 (en)	1995-06-15	2004-08-31	Crucell Holland B.V.	Packaging systems for human recombinant adenovirus to be used in gene therapy
AUPN477695A0 (en) *	1995-08-14	1995-09-07	Commonwealth Scientific And Industrial Research Organisation	Gene therapy
FR2748753B1 (fr) *	1996-05-20	1998-08-14	Transgene Sa	Nouveaux vecteurs adenoviraux pour la therapie genique
US6730662B1 (en)	1996-07-05	2004-05-04	Mcgill University	Adenovirus E4 proteins for inducing cell death
DE69725882T2 (de) *	1996-07-05	2004-07-29	Branton, Philip E., St. Lambert	Adenovirus e4 proteine für induktion von zelltod
AU4255397A (en) *	1996-09-06	1998-03-26	Trustees Of The University Of Pennsylvania, The	Chimpanzee adenovirus vectors
FR2755699B1 (fr) *	1996-11-08	1998-12-18	Rhone Poulenc Rorer Sa	Nouvelles constructions et vecteurs pour l'expression ciblee et inductible des genes
US5981275A (en) *	1997-04-14	1999-11-09	Genzyme Corporation	Transgene expression system for increased persistence
KR20010020342A (ko)	1997-04-28	2001-03-15	자끄 사비나	종양치료용 맥관형성 길항제의 아데노바이러스-매개 종양내 전달방법
US6696423B1 (en)	1997-08-29	2004-02-24	Biogen, Inc.	Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
FR2774699B1 (fr)	1997-11-17	2003-10-03	Rhone Poulenc Rorer Sa	Methode de reduction des evenements de recombinaison homologue
ES2180258T3 (es)	1998-07-07	2003-02-01	Transgene Sa	Utilizacion de pautas de lectura abierta adenovirales de e4 para mejorar la expresion de genes.
US6461869B1 (en) *	1999-07-20	2002-10-08	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Purging leukemia cells from hematopoietic stem cells
FR2799472B1 (fr) *	1999-10-07	2004-07-16	Aventis Pharma Sa	Preparation d'adenovirus recombinants et de banques adenovirales
GB0018307D0 (en)	2000-07-26	2000-09-13	Aventis Pharm Prod Inc	Polypeptides
JP4744771B2 (ja) *	2000-05-26	2011-08-10	大日本住友製薬株式会社	副作用を軽減した新規な組換えアデノウイルスベクター
US20030158112A1 (en)	2002-02-15	2003-08-21	Johns Hopkins University School Of Medicine	Selective induction of apoptosis to treat ocular disease
WO2006060089A2 (en) *	2004-10-25	2006-06-08	Biogen Idec Ma Inc.	Novel methods for producing adenoviral vector preparations with reduced replication-competent adenovirus contamination and novel adenoviral vectors and preparations
US8329669B2 (en)	2006-07-28	2012-12-11	Sanofi	Composition and method for treatment of tumors
WO2012021730A2 (en) *	2010-08-11	2012-02-16	Genvec, Inc.	Respiratory syncytial virus (rsv) vaccine
KR101667094B1 (ko) *	2010-08-16	2016-10-17	더 솔크 인스티튜트 포 바이올로지칼 스터디즈	항암 아데노바이러스
AU2014236207B2 (en)	2013-03-14	2019-05-23	Salk Institute For Biological Studies	Oncolytic adenovirus compositions
EP3390428B1 (en)	2016-02-23	2019-09-25	Salk Institute for Biological Studies	High throughput assay for measuring adenovirus replication kinetics
WO2017147269A1 (en)	2016-02-23	2017-08-31	Salk Institute For Biological Studies	Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2018111767A1 (en)	2016-12-12	2018-06-21	Salk Institute For Biological Studies	Tumor-targeting synthetic adenoviruses and uses thereof
TW201907937A (zh)	2017-05-08	2019-03-01	美商葛利史東腫瘤科技公司	阿爾法病毒新抗原載體
CN118955720A (zh)	2018-01-04	2024-11-15	伊科尼克治疗公司	抗组织因子抗体、抗体-药物缀合物及相关方法
AU2019251356B2 (en)	2018-04-09	2025-06-12	Salk Institute For Biological Studies	Oncolytic adenovirus compositions with enhanced replication properties
JP7457733B2 (ja)	2019-05-30	2024-03-28	グリットストーンバイオインコーポレイテッド	改変アデノウイルス
AU2021320896A1 (en)	2020-08-06	2023-03-23	Seattle Project Corp.	Multiepitope vaccine cassettes
KR102808930B1 (ko)	2021-01-21	2025-05-19	주식회사 셀리드	복제가능 아데노바이러스를 포함하지 않는 신규 아데노바이러스 벡터 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5670488A (en) *	1992-12-03	1997-09-23	Genzyme Corporation	Adenovirus vector for gene therapy
FR2704234B1 (fr) *	1993-04-22	1995-07-21	Centre Nat Rech Scient	Virus recombinants, preparation et utilisation en therapie genique.
FR2705361B1 (fr) *	1993-05-18	1995-08-04	Centre Nat Rech Scient	Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) *	1993-05-28	1995-08-18	Transgene Sa	Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2726285B1 (fr) *	1994-10-28	1996-11-29	Centre Nat Rech Scient	Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
US5707618A (en) *	1995-03-24	1998-01-13	Genzyme Corporation	Adenovirus vectors for gene therapy

1994
- 1994-10-28 FR FR9413355A patent/FR2726285B1/fr not_active Expired - Fee Related
1995
- 1995-10-25 US US08/817,575 patent/US6312946B1/en not_active Expired - Fee Related
- 1995-10-25 FI FI971783A patent/FI971783A7/fi not_active IP Right Cessation
- 1995-10-25 EP EP95936609A patent/EP0787199A1/fr not_active Withdrawn
- 1995-10-25 CN CN95195913A patent/CN1110564C/zh not_active Expired - Fee Related
- 1995-10-25 MX MX9702553A patent/MX9702553A/es not_active IP Right Cessation
- 1995-10-25 WO PCT/FR1995/001415 patent/WO1996013596A1/fr not_active Application Discontinuation
- 1995-10-25 JP JP8514357A patent/JPH10507922A/ja not_active Ceased
- 1995-10-25 AU AU38477/95A patent/AU703539B2/en not_active Ceased
- 1995-10-25 KR KR1019970702755A patent/KR100424803B1/ko not_active Expired - Fee Related
- 1995-10-26 ZA ZA959086A patent/ZA959086B/xx unknown
- 1995-10-26 IL IL11577995A patent/IL115779A0/xx not_active IP Right Cessation
1997
- 1997-04-17 NO NO19971764A patent/NO320090B1/no unknown
2001
- 2001-01-26 US US09/769,352 patent/US6482617B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU703539B2 (en)	1999-03-25
EP0787199A1 (fr)	1997-08-06
FR2726285B1 (fr)	1996-11-29
IL115779A0 (en)	1996-01-19
NO320090B1 (no)	2005-10-24
US6482617B2 (en)	2002-11-19
MX9702553A (es)	1997-06-28
WO1996013596A1 (fr)	1996-05-09
NO971764L (no)	1997-04-17
US20010039046A1 (en)	2001-11-08
KR970707292A (ko)	1997-12-01
ZA959086B (en)	1996-07-16
KR100424803B1 (ko)	2004-06-12
CN1110564C (zh)	2003-06-04
AU3847795A (en)	1996-05-23
JPH10507922A (ja)	1998-08-04
US6312946B1 (en)	2001-11-06
FI971783L (fi)	1997-04-25
FR2726285A1 (fr)	1996-05-03
CN1162338A (zh)	1997-10-15
FI971783A7 (fi)	1997-04-25
NO971764D0 (no)	1997-04-17

Publication	Publication Date	Title
FI971783A0 (fi)	1997-04-25	Adenoviruksia, joissa ei ole elinkykyisiä kontaminoivia partikkeleita, niiden valmistus ja käyttöjä
MX9201235A (es)	1992-10-01	Procedimiento para la fabricacion de boehmita dispersable.
EE9900014A (et)	1999-08-16	Erütromütsiinid ja nende valmistamise protsess
FI972164A7 (fi)	1997-07-21	Aerogeelipitoinen komposiittimateriaali, menetelmä sen valmistamiseksi ja sen käyttö
FI972165A7 (fi)	1997-07-21	Aerogeelipitoinen komposiittimateriaali, menetelmä sen valmistamiseksi ja sen käyttö
FI972087A0 (fi)	1997-05-15	Dihydropyrimidiineja ja niiden käyttöjä
FI944310A0 (fi)	1994-09-16	Heteroaryyliamino- ja heteroaryylisuolfonamidosubstituoituja 3-bentsyyliaminometyylipiperidiinejä ja vastaavia yhdisteitä
TR199501568A2 (tr)	1996-07-21	Tasikinin öncüleri.
FI923775A7 (fi)	1993-02-24	2-piperatsinoniyhdisteet, niiden valmistus ja käyttö
FI970150A7 (fi)	1997-01-14	Substituoituja pyrimidiiniyhdisteitä ja niiden käyttö
FI925913L (fi)	1994-06-30	Menetelmä -olefiinien polymeroimiseksi sekä esipolymeroitu katalyyttikompositio ja menetelmä tämän valmistamiseksi
FI972629A7 (fi)	1997-06-18	Aryyli- ja heteroaryylisulfonamidijohdoksia, niiden valmistus ja niiden käyttö endoteliinin antagonisteina
EE200000621A (et)	2002-06-17	Pikornaviirusevastased ühendid, nende valmistamine ja kasutamine
FI951817A7 (fi)	1995-10-16	Orgonaluminoksituote, sen valmistus ja käyttö
FI980246A7 (fi)	1998-08-11	Menetelmä keittimen käyttämiseksi ja keitin
HU9500063D0 (en)	1995-03-28	Alfa-pyrimidinyl acrylic acid derivatives, the preparation thereof and their use as fungicide
FI934680A7 (fi)	1993-10-22	Aryylimorfoliini, valmistus ja käyttö
FI954946L (fi)	1996-04-20	Kinoksaliinit, menetelmä niiden valmistamiseksi ja niiden käyttö
FI960133A7 (fi)	1996-03-11	Matriisiin sidottu partikkelivalmiste
FI914526A7 (fi)	1992-03-27	Yhdiste, sen valmistus ja käyttö
FI953391L (fi)	1996-01-13	Komposiittimateriaali, menetelmä sen valmistamiseksi ja sen käyttö
EE9600180A (et)	1997-06-16	Anti-HIV kompositsioon, meetod selle valmistamiseks ja selle kasutamine
FI924053A7 (fi)	1993-03-15	Substituoidut aminopropaanit, menetelmä niiden valmistamiseksi ja niiden käyttö
FI930238A7 (fi)	1993-07-23	N-5-suojatut 2,5-diamino-4,6-diklooripyrimidiinit ja menetelmä niiden valmistamiseksi
FI914525A7 (fi)	1992-03-27	Yhdiste, käyttö ja valmistus

Legal Events

Date	Code	Title	Description
2008-04-30	MA	Patent expired